Marisa Wexler MS,  —

One year of treatment with Rinvoq (upadacitinib) reduced disease activity for most adults with non-radiographic axial spondyloarthritis (nr-axSpA) — an inflammatory condition related to ankylosing spondylitis (AS) — in a Phase 3 clinical trial. “These longer-term results continue to support the favorable benefit-risk profile of [Rinvoq] once daily…

Machine learning and deep learning are already showing promise as tools to help diagnose and manage ankylosing spondylitis (AS), though the field is still in its infancy and more work must be done, a new review paper highlights. The paper, “Machine Learning and Deep Learning for…

Up to five years of treatment with bimekizumab safely leads to sustained reductions in symptoms and disease activity, as well as improvements in physical function and life quality, for people with ankylosing spondylitis (AS). That’s according to new data from the now-completed Phase 2b BE AGILE clinical…

People with ankylosing spondylitis (AS) who carry a mutation in the gene that encodes the CARD9 protein may be more likely to respond to treatments that block an inflammatory signaling molecule known as interleukin-17 (IL-17), a preclinical study suggests. Scientists found that the protein CARD9 is involved in…

A form of exercise using a device that mimics horseback riding may be an effective intervention to boost muscle strength, limit disease severity, and improve life quality for people with ankylosing spondylitis (AS), according to a new study. The novel approach tested in the trial uses a device called…

Treatment with Rinvoq (upadacitinib) substantially reduced disease activity for most adults with ankylosing spondylitis (AS) who had failed to respond to other treatments, according to one-year data from a clinical trial. “These 1-year data demonstrated consistent improvement and maintenance of response with [Rinvoq] treatment in treatment-refractory patients…

More than a dozen genes related to inflammatory cell death were found to be expressed at atypical levels in ankylosing spondylitis (AS) patients in a new study, suggesting these genes could be used to help diagnose the disease. The analyses also identified three small molecules that may help to…

Seven genes — from a pool of four dozen identified as being different in people with ankylosing spondylitis (AS) — may be potential genetic biomarkers for this rare type of arthritis, according to a new study done based on computer analyses. The study also uncovered several molecules that may…

Machine learning methods may help in the early detection of ankylosing spondylitis (AS), a new study reported. “It’s fantastic to see the cutting-edge role that machine learning can play in the early identification of patients with health conditions such as AS … Though it is in its early stages,…

When combined with modern evidence-based medicine, treatment with the traditional Chinese herbal medicine Duhuo Jisheng decoction may help relieve pain and improve mobility in people with ankylosing spondylitis (AS), according to an analysis of clinical trial data. “Current evidence suggests that [Duhuo Jisheng decoction] combined with Western medicine is…